Eculizumab was started between 35 and 61 days following the onset of the NMOSD attack and partially reduced the symptoms of all 5 patients. Eculizumab treatment may reduce the symptoms of ...

Differentiating POEMS syndrome from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is important because both have similar demyelinating features but require different treatments.

The results correct a misconception in the ACR/EULAR criteria for IgG4-RD that list hypocomplementemia as a feature limited to patients with renal involvement. A new study has found that ...

Both predictive models suggest that tryptase, alkaline phosphatase, and bilirubin are key indicators of disease severity in SM. Researchers have developed 2 new predictive models using peripheral ...

A patient with PLA2R-positive membranous nephropathy later developed IgG4-related autoimmune pancreatitis and renal masses, which resolved with glucocorticoid therapy. Glucocorticoid therapy ...

Are the out-of-pocket costs of your medications taking a toll on your finances? Rising drug costs are happening to many people with neurological diseases, but people with multiple sclerosis (MS) ...

Bezuclastinib significantly reduced mast cell burden and improved nonadvanced SM symptoms compared with placebo. Treatment with 100 mg of bezuclastinib improved clinical outcomes and reduced mast cell ...

When I’m out in public, whether it be a doctor’s office or a clothing store, I usually have to deal with people ogling my scooter. I understand that I look a little different and that the way I have ...

Early diagnosis is vital in AAV with interstitial lung disease so that treatment can begin as soon as possible. Patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) ...

Now that I’m in my 30s, navigating life with a progressive muscle disease like limb-girdle muscular dystrophy (LGMD) has been emotionally and mentally challenging. The fear of losing close family, or ...

Leukocytosis, thrombocytopenia, low serum albumin, and the presence of a mutation involving the SRSF2 or TP53 genes were independent predictors of worse overall survival in patients with myelofibrosis ...

JAK inhibitor therapy at the start of conditioning led to significantly higher early B-cell recovery and significantly increased late recovery of gamma-delta T cells and natural killer cells in ...